Basic information Safety Related Supplier

ChemicalBook Product Catalog Natural Products Terpenes Nagilactone B

1/1

Nagilactone B NEW

$ 1298.00 /2mg

Min. Order
Purity
Cas No19891-51-1
Supply Ability10g
Update time2025-10-27

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP4Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Nagilactone B
CAS No	19891-51-1
EC-No
Min. Order
Purity
Supply Ability	10g
Release date	2025/10/27

Product Introduction

Bioactivity

Name	Nagilactone B
Description	Nagilactone B is extracted from the root bark of Podocarpus nagi and it also is a liver X receptor (LXR) agonist.
In vitro	Nagilactone B (NLB) significantly ameliorates intracellular lipid accumulation. Nagilactone B (0.02, 0.1, and 0.5?μM) markedly promotes cholesterol efflux to extracellular apolipoprotein A-I (apoA-I) and high density lipoprotein (HDL) with maximal 5.72- (P<0.05) and 2.34-fold (P<0.01), respectively. RAW264.7 cells are co-incubated with oxLDL (20?μg/mL) and Nagilactone B (0.02, 0.1, and 0.5?μM) for 24?h. ORO positive areas are reduced by 30.05±7.49 (P<0.01), 47.25±5.39 (P<0.001), and 48.65±7.44% (P<0.001) in Nagilactone B (0.02, 0.1, and 0.5 μM)-treated groups, respectively .
In vivo	Nagilactone B (NLB) inhibits atherosclerosis in apoE-/- mice by inducing ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) mediated cholesterol efflux in macrophages. Nagilactone B treatment (10 and 30 mg/kg/day) obviously decreases en face aortic lesions, compared with the HFD group by 54.96±10.06% (P<0.01), 71.50±15.37% (P<0.001) in both NLB (L) and NLB (H) groups. In particular, Nagilactone B markedly attenuates atherosclerotic plaque lesion areas in the aortic arch aorta, thoracic aorta, and abdominal aorta [P<0.01 in NLB (H) group]. Male apoE-deficient mice on C57BL/6J background receive Nagilactone B (10 and 30?mg/kg) for 12 weeks. Compared with the model group, Nagilactone B treatment (10 and 30?mg/kg) significantly decreases en face lesions of total aorta areas. Six-week-old male apoE-/- mice on an HFD are randomized to receive Atorvastatin (10 mg/kg/day), Nagilactone B (10 and 30?mg/kg/day), or CMC-Na for 12 weeks. Mice on a chow diet are administered CMC-Na as the normal diet control group .
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Keywords	Nagilactone B \| LXR
Inhibitors Related	SR9243 \| GW6340 \| T0901317 \| GSK3987 \| Taraxasterol \| SR9238 \| GSK2033 \| BE1218 \| (20S)-Protopanaxatriol \| IMB-808 \| GW3965 hydrochloride \| Rovazolac

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book